Surgery for a one-eye surface tumor in people with HIV
Part of Cancer, Eyes & vision, Infections clinical trials.
This study looks at whether removing a suspected pre-cancer/cancer growth on the surface of the eye can be done safely in people living with HIV. It is a feasibility (safety and practical) study, helping doctors refine the best surgical approach and follow-up.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a suspected OSSN (ocular surface squamous neoplasia) growth in only one eye
- A study eye specialist must confirm the growth can be removed with small safety margins and without affecting key inner eye surface areas
- You are living with HIV and can show proof of HIV testing or treatment (ART) within required documentation rules
- You should be well enough to do daily activities (WHO performance status 0–2)
- You should not have had other investigational medicines in the last 30 days (ART trial meds allowed)
- You should not have certain past eye growths (like prior OSSN or other eye cancers) and should not have uncontrolled medical problems or issues that would stop follow-up
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether a “sentinel lymph node biopsy” can better detect cancer spread in people with specific cancers of the eye surface and nearby tissues. It may help doctors find the right next treatment by learning whether lymph nodes are involved.
This study tests two different approaches to treating early cervical changes in women living with HIV who tested positive for HPV (a virus that can cause cervical cancer). The goal is to see which approach works better and is easier to use in South Africa.
This trial is testing new treatments for cryptococcal meningitis, a serious brain infection, in people living with HIV. It aims to find the best way to treat this infection with fewer side effects.
This study tests different ways to screen for HPV (a virus linked to cervical cancer) in women living with HIV. The goal is to find the best, most practical screening approach to catch cervical problems early.
This trial tests an experimental drug called ACU-D1 for people with HIV who have high-grade abnormal cell growth (HSIL) on their vulva or perianal area. The goal is to see if the drug can help treat these HPV-related lesions.
This study tests if a probiotic called EXE-346 can help clear anal high-grade squamous intraepithelial lesions (HSIL), a precancerous condition, in people with HIV who are on effective antiretroviral therapy. If you have anal HSIL that wasn't fully removed by biopsy, you may be able to join.
Hear when a new HPV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.